about
Magnetic resonance imaging and image analysis for assessment of HPMC matrix tablets structural evolution in USP Apparatus 4.Formulation and evaluation of Bacillus coagulans-loaded hypromellose mucoadhesive microspheres.Characterization of the substitution pattern of cellulose derivatives using carbohydrate-binding modules.Biomagnetic methods: technologies applied to pharmaceutical research.Factors affecting drug release from hydroxypropyl methylcellulose matrix systems in the light of classical and percolation theories.Development of gastro intestinal sustained release tablet formulation containing acryl-EZE and pH-dependent swelling HPMC K 15 M.Drug release from matrix tablets: physiological parameters and the effect of food.Co-processing as a tool to improve aqueous dispersibility of cellulose ethers.Preparation and characterization of a coacervate extended-release microparticulate delivery system for Lactobacillus rhamnosus.Evaluation and comparison of physicomechanical characteristics of gelatin and hypromellose capsules.Effects of thermal curing conditions on drug release from polyvinyl acetate-polyvinyl pyrrolidone matrices.A new application of lipid nanoemulsions as coating agent, providing zero-order hydrophilic drug release from tablets.Preparation and in vitro evaluation of guar gum based triple-layer matrix tablet of diclofenac sodium.Release kinetics of papaverine hydrochloride from tablets with different excipients.Roller compaction of hydrophilic extended release tablets-combined effects of processing variables and drug/matrix former particle sizeMatrix tablets: the effect of hydroxypropyl methylcellulose/anhydrous dibasic calcium phosphate ratio on the release rate of a water-soluble drug through the gastrointestinal tract I. In vitro tests.Investigation of the effects of hydroalcoholic solutions on textural and rheological properties of various controlled release grades of hypromelloseMultiple unit particles system of ramipril: an approach to enhance stability.Iatrogenic thyrotoxicosis secondary to compounded liothyronine.Advanced formulation design of venlafaxine hydrochloride coated and triple-layer tablets containing hypromellose.Formulation development and stability studies of norfloxacin extended-release matrix tablets.Extended release of flurbiprofen from tromethamine-buffered HPMC hydrophilic matrix tablets.The influence of hydro-alcoholic media on hypromellose matrix systems.Evaluating the swelling, erosion, and compaction properties of cellulose ethers.Self-Emulsifying Granules and Pellets: Composition and Formation Mechanisms for Instant or Controlled Release.Multifractal Characterization of Pharmaceutical Hot-Melt Extrudates.Advances in mechanistic understanding of release rate control mechanisms of extended-release hydrophilic matrix tablets.Prolonged-release minitablets with carbamazepine - preliminary observations in vitro.Development of a Sustained Release Solid Dispersion Using Swellable Polymer by Melting Method.Film-coated matrix mini-tablets for the extended release of a water-soluble drug.In vitro release of ketoprofen from hydrophilic matrix tablets containing cellulose polymer mixturesHow much weighs the swelling pressure
P2860
Q33779228-9F8542A7-AA9A-4525-942C-729B929B66C3Q35023317-08778E22-E4FF-4A6E-B492-450A3F9DD3B5Q35533950-3C98555A-5D8C-4A6E-AE5E-0118516142E2Q37800414-A4865B7B-FE2F-40F4-BBB4-3842C4EB2F4EQ37803215-2255BDAC-35EF-4AC8-9F86-A2F71A7356E9Q37943016-21EC4E90-4715-4673-89B6-77E121109A4BQ38223664-6E081500-C0CF-46BC-A12A-FC97DA33D8E7Q38544845-1A650491-4E9F-43C5-B0E5-9D759F92D4A9Q38607975-2F3FD4C4-FCAD-4B1E-BB08-B054BBD53086Q39270787-17D9E697-08B4-4790-9D39-77CAE3540E18Q39923015-7AF5F853-5B2B-4ABF-8D46-2C1C004B30B7Q40512138-88B1A57A-882A-4FAD-BA18-DCC519EDAA21Q41406355-98E287E8-DB78-4D12-9350-3E8EAD24DD59Q41827095-C8088D6C-3EF4-493C-89ED-162B90585743Q41950429-4B1AB03B-A397-4595-8DC2-473114A5C136Q41988214-1B42774A-AC73-412C-B7D3-467B58963B52Q42044494-B8128A98-378E-41AB-BEF5-38B0E32EE933Q42771714-C64114BF-AAB7-49C9-AF59-EB1BA5A8D6C4Q43177179-050F9761-401E-405B-9480-E8D904C8AF5AQ43250327-5C484445-832B-4C6C-8DC0-11E2A755BD79Q45032510-FF94D875-1106-4834-8273-8A3FCE461146Q46403625-457142CE-B6F9-4FF2-AE15-7EEA829070F0Q46929756-84C6FBB7-D545-4420-B58C-A1CECF65FF75Q47594363-C7196989-1027-4569-B7FE-6131F35EAC6CQ48368186-23E977C6-76BD-430B-9802-DE719AA291A1Q50275846-3F2E757F-DA2D-47A6-A861-7F1E8324C8C5Q50606382-8189DB43-3D3A-4AF2-AC6B-148E2F98FA58Q50861442-6433A08F-CA07-47D5-BDA5-1F5C4723A40BQ51812821-5BC0E10E-C328-43C8-9F3B-0CAF9B72EC24Q53744932-C769FF52-5FE1-49AE-989A-5CCE45A8482EQ57165527-EDA286C4-1739-4042-BD67-5CF24EB6C723Q57347317-A780266E-FC5B-4034-B9AA-02EE129EB41D
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The use of hypromellose in oral drug delivery.
@ast
The use of hypromellose in oral drug delivery.
@en
type
label
The use of hypromellose in oral drug delivery.
@ast
The use of hypromellose in oral drug delivery.
@en
prefLabel
The use of hypromellose in oral drug delivery.
@ast
The use of hypromellose in oral drug delivery.
@en
P2093
P2860
P356
P1476
The use of hypromellose in oral drug delivery.
@en
P2093
James L Ford
Luigi G Martini
Matthew Roberts
P2860
P304
P356
10.1211/0022357055957
P577
2005-05-01T00:00:00Z